Application of SPET using technetium-99m sestamibi in brain tumours and comparison with expression of the MDR-1 gene: Is it possible to predict the response to chemotherapy in patients with gliomas by means of 99mTc-sestamibi SPET?

European Journal of Nuclear Medicine

Volumn 25, Issue 4, 1998, Pages 401-409

  Yokogami, Kiyotaka ^a,b   Kawano, Hirokazu ^a   Moriyama, Takuzou ^a   Uehara, Hisao ^a   Sameshima, Tetsurou ^a   Oku, Takamitsu ^a   Goya, Tomokazu ^a   Wakisaka, Shinichiro ^a   Nagamachi, Shigeki ^a   Jinnouchi, Seishi ^a   Tamura, Shouzou ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Brain tumour; MDR 1; P glycoprotein; Single photon emission tomography; Technetium 99m sestamibi

Indexed keywords

ANTINEOPLASTIC AGENT; GLYCOPROTEIN P; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; THALLIUM 201;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; BRAIN TUMOR; CANCER GRADING; CLINICAL ARTICLE; FEMALE; GENE EXPRESSION; GLIOBLASTOMA; GLIOMA; HUMAN; IMAGE QUALITY; IMMUNOHISTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; MALE; PUMP; SIGNAL NOISE RATIO; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

AGED; BLOTTING, NORTHERN; BRAIN NEOPLASMS; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; GENES, MDR; GLIOBLASTOMA; HUMANS; IMMUNOENZYME TECHNIQUES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; P-GLYCOPROTEIN; POLYMERASE CHAIN REACTION; RADIOPHARMACEUTICALS; RNA, MESSENGER; TECHNETIUM TC 99M SESTAMIBI; THALLIUM RADIOISOTOPES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 15144350614     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050238     Document Type: Article

References (66)

1. O'Tuama LA, Trêves ST, Larar JN, et al. Thallium-201 versus technetium-99m-MIBI SPET in evaluation of childhood brain tumours: a within-subject comparison. J Nucl Med 1993; 34: 1045-1051.
2. Jinnouchi S, Hoshi H, Ohnishi T, et al. Thallium-201 SPET for predicting histological types of meningiomas. J Nucl Med 1993; 34: 2091-2094.
3. Ueda T, Kaji Y, Wakisaka S, et al. Time sequential single photon emission computed tomography studies in brain tumour using thallium-201. Eur J Nucl Med 1993; 20: 138-145.
4. Oriuchi N, Tamura M, Shibazaki T, et al. Clinical evaluation of thallium-201 SPET in supratentorial gliomas: relationship to histologic grade, prognosis and proliferative activities [see comments]. J Nucl Med 1993; 34: 2085-2089.
5. Podoloff DA, Kim EE, Haynie TP. SPET in the evaluation of cancer patients: not quo vadis; rather, ibi fere summus. Radiology 1992; 183: 305-317.
6. Delmon ML, Piwnica WD, Van dAA, Holman BL, Davison A, Jones AG. Uptake of the cation hexakis(2-methoxyiso-butylisonitrile)-technetium-99m by human carcinoma cell lines in vitro. Cancer Res 1990; 50: 2198-2202.
7. Moretti JL, Caglar M, Boaziz C, Caillat VN, Morere JF. Sequential functional imaging with technetium-99m hexakis-2-methoxyisobutylisonitrile and indium-111 octreotide: can we predict the response to chemotherapy in small cell lung cancer? Eur J Nucl Med 1995; 22: 177-180.
8. Baillet G, Albuquerque L, Chen Q, Poisson M, Delattre JY. Evaluation of single-photon emission tomography imaging of supratentorial brain gliomas with technetium-99m sestamibi. Eur J Nucl Med 1994; 21: 1061-1066.
9. Bagni B, Pinna L, Tamarozzi R, et al. SPET imaging of intracranial tumours with 99Tcm-sestamibi. Nucl Med Commun 1995; 16: 258-264.
10. 99mTc-sestamibi in oncology. Tumori 1996; 82: 12-21.
11. Maffioli L, Gasparini M, Chiti A, et al. Clinical role of technetium-99m sestamibi single-photon emission tomography in evaluating pretreated patients with brain tumours. Eur J Nucl Med 1996; 23: 308-311.
12. Shih WJ, Kadzielawa K, Lee C, Moody EB, Ryo UY. Tc-99m sestamibi uptake by cerebellar metastasis from bronchogenic carcinoma. Clin Nucl Med 1993; 18: 887-890.
13. Hassan IM, Sahweil A, Constantinides C, et al. Uptake and kinetics of Tc-99m hexakis 2-methoxy isobutyl isonitrile in benign and malignant lesions in the lungs. Clin Nucl Med 1989; 14: 333-340.
14. Park CH, Kim SM, Zhang J, McEwan JR, Intenzo C. Tc-99m MIBI brain SPET of an acoustic schwannoma. Clin Nucl Med 1994; 19: 152-154.
15. Park CH, Kim SM, Zhang JJ, Intenzo CM, McEwan JR. Tc-99m MIBI brain SPET in the diagnosis of recurrent glioma. Clin Nucl Med 1994; 19: 57-58.
16. Aktolun C. Tc-99m sestamibi imaging is useful in brain metastases [letter; comment]. Clin Nucl Med 1994; 19: 1033-1034.
17. Matsui R, Komori T, Narabayashi I, et al. Tc-99m sestamibi uptake by malignant lymphoma and slow washout. Clin Nucl Med 1995; 20: 352-356.
18. Pirro JP, Di RR, Narra RK, Nunn AD. Relationship between in vitro transendothelial permeability and in vivo single-pass brain extraction. J Nucl Med 1994, 35: 1514-1519.
19. Cordon CC, O'Brien JP, Casals D, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989; 86: 695-698.
20. Piwnica WD, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 1993; 53: 977-984.
21. Fojo A, Hamilton TC, Young RC, Ozols RF. Multidrug resistance in ovarian cancer. Cancer 1987; 60: 2075-2080.
22. Lai GM, Chen YN, Mickley LA, Fojo AT, Bates SE. P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines. Int J Cancer 1991; 49: 696-703.
23. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159.
24. Abe Y, Nakamura M, Ota E, et al. Expression of the multidrug resistance gene (MDR-1) in non-small cell lung cancer. Jpn J Cancer Res 1994; 85: 536-541.
25. Backus M, Piwnica WD, Hockett D, et al. Microprobe analysis of Tc-MIBI in heart cells: calculation of mitochondrial membrane potential. Am J Physiol 1993.
26. Chernoff DM, Strichartz GR, Piwnica WD. Membrane potential determination in large unilamellar vesicles with hexakis(2-methoxyisobutylisonitrile)technetium(I). Biochim Biophys Acta 1993; 1147: 262-266.
27. 99mTc-sestamibi in cultured chick ventricular myocytes during ATP depletion. Circulation 1992; 85: 1531-1541.
28. Carvalho PA, Chiu ML, Kronauge JF, et al. Subcellular distribution and analysis of technetium-99m-MIBI in isolated perfused rat hearts. J Nucl Med 1992; 33: 1516-1522.
29. Piwnica WD, Kronauge JF, Chiu ML. Enhancement by tetraphenylborate of technetium-99m-MIBI uptake kinetics and accumulation in cultured chick myocardial cells. J Nucl Med 1991; 32: 1992-1999.
30. Piwnica WD, Kronauge JF, Chiu ML. Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) technetium(I) in cultured chick myocardial cells. Mitochondrial and plasma membrane potential dependence. Circulation 1990; 82: 1826-1838.
31. Chiu ML, Kronauge JF, Piwnica WD. Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutylisonitrile) technetium(I) in cultured mouse fibroblasts. J Nucl Med 1990; 31: 1646-1653.
32. Piwnica WD, Holman BL. Noncardiac applications of hexakis(alkylisonitrile) technetium-99m complexes [comment]. J Nucl Med 1990; 31: 1166-1167.
33. Piwnica WD, Kronauge JF, Delmon L, Holman BL, Marsh JD, Jones AG. Effect of metabolic inhibition on technetium-99m-MIBI kinetics in cultured chick myocardial cells. J Nucl Med 1990; 31: 464-472.
34. Siegal T, Sandbank U, Gabizon A, et al. Alteration of blood-brain-CSF barrier in experimental meningeal carcinomatosis. A morphologic and adriamycin-penetration study. J Neurooncol 1987; 4: 233-242.
35. Blasberg RG, Groothuis DR. Chemotherapy of brain tumours: physiological and pharmacokinetic considerations. Semin Oncol 1986; 13: 70-82.
36. Ushio Y, Posner JB, Shapiro WR. Chemotherapy of experimental meningeal carcinomatosis. Cancer Res 1977; 37: 1232-1237.
37. Levin VA, Wilson CB. Chemotherapy: the agents in current use. Semin Oncol 1975; 2: 63-67.
38. Levin VA. A pharmacologic basis for brain tumour chemotherapy. Semin Oncol 1975; 2: 57-61.
39. Levin VA, Freeman DM, Landahl HD. Permeability characteristics of brain adjacent to tumours in rats. Arch Neural 1975; 32: 785-791.
40. Stewart DJ. A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumours. J Neurooncol 1994; 20: 121-139.
41. Berry I, Gaillard JF, Guo Z, et al. Cerebral lesions in AIDS: what can be expected from scintigraphy? Cerebral tomographic scintigraphy using thallium-201: a contribution to the differential diagnosis of lymphomas and infectious lesions. J Neuroradiol 1995; 22: 218-228.
42. Dierckx RA, Martin JJ, Dobbeleir A, Crols R, Neetens I, De Deyn PP. Sensitivity and specificity of thallium-201 single-photon emission tomography in the functional detection and differential diagnosis of brain tumours. Eur J Nucl Med 1994; 21: 621-633.
43. Scopinaro F, Schillaci O, Scarpini M, et al. Technetium-99m sestamibi: an indicator of breast cancer invasiveness. Eur J Nucl Med 1994; 21: 984-987.
44. cm-MIBI uptake in green plants. Nucl Med Commun 1994; 15: 905-915.
45. Bates SE, Shieh CY, Tsokos M. Expression of mdr-1/P-glycoprotein in human neuroblastoma. Am J Pathol 1991, 139: 305-315.
46. Berger W, Elbling L, Minai PM, et al. Intrinsic MDR-1 gene and P-glycoprotein expression in human melanoma cell lines. Int J Cancer 1994; 59: 717-723.
47. Benson MC, Giella J, Whang IS, et al. Flow cytometric determination of the multidrug resistant phenotype in transitional cell cancer of the bladder: implications and applications. J Urol 1991; 146: 982-986.
48. Cheng AL, Su IJ, Chen YC, Lee TC, Wang CH. Expression of P-glycoprotein and glutathione-S-transferase in recurrent lymphomas: the possible role of Epstein-Barr virus, immunophenotypes, and other predisposing factors. J Clin Oncol 1993; 11: 109-115.
49. Dong Z, Radinsky R, Fan D, et al. Organ-specific modulation of steady-state mdr gene expression and drug resistance in murine colon cancer cells. J Natl Cancer Inst 1994; 86: 913-920.
50. Duensing TD, Slate DL. Intracellular expression of P-glyco-protein in a human colon tumour cell line. Anticancer Res 1994; 14: 13-19.
51. Herzog CE, Tsokos M, Bates SE, Fojo AT. Increased mdr-1/P-glycoprotein expression after treatment of human colon carcinoma cells with P-glycoprotein antagonists. J Bio! Chem 1993; 268: 2946-2952.
52. Kacinski BM, Yee LD, Carter D, Li D, Kuo MT. Human breast carcinoma cell levels of MDR-1 (P-glycoprotein) transcripts correlate in vivo inversely and reciprocally with tumour progesterone receptor content. Cancer Commun 1989; 1: 1-6.
53. Kaczorowski S, Kaczorowska M. P glycoprotein and multidrug resistance [in Polish]. Patol Pol 1991; 42: 119-125.
54. Kandel RA, Campbell S, Noble TS, Bell R, Andrulis IL. Correlation of p-glycoprotein detection by immunohistochemistry with mdr-1 mRNA levels in osteosarcomas. Pilot study. Diagn Mol Pathol 1995; 4:59-65.
55. Kaye SB, Kerr DJ. Multidrug resistance: clinical relevance in haematological malignancies. Blood Rev 1991; 5: 38-41.
56. Niehans GA, Jaszcz W. Brunetto V, et al. Immunohistochemical identification of P-glycoprotein in previously untreated. diffuse large cell and immunoblastic lymphomas. Cancer Res 1992; 52: 3768-3775.
57. Radosevich JA, Robinson PG, Rittmann GL, et al. Immunohistochemical analysis of pulmonary and pleural tumors with the monoclonal antibody HYB-612 directed against the multidrug resistance (MDR-1) gene product, P-glycoprotein. Tumour Biol 1989; 10: 252-257.
58. Ramachandran C, Mead D, Wellham LL, Sauerteig A, Krishan A. Expression of drug resistance-associated mdr-1, GST pi, and topoisomerase II genes during cell cycle traverse. Biochem Pharmacol 1995; 49: 545-552.
59. Saito T, Hikita M, Kohno K, Sato S, Takano H, Kobayashi M. Different sensitivities of human esophageal cancer cells to multiple anti-cancer agents and related mechanisms. Cancer 1992; 70: 2402-2409.
60. Scala S, Budillon A, Zhan Z, et al. Downregulation of mdr-1 expression by 8-Cl-cAMP in multidrug resistant MCF-7 human breast cancer cells. J Clin Invest 1995; 96: 1026-1034.
61. Schadendorf D, Makki A, Stahr C, et al. Membrane transport proteins associated with drug resistance expressed in human melanoma. Am J Pathol 1995; 147: 1545-1552.
62. Wishart GC, Kaye SB. Is multidrug resistance relevant in breast cancer? Eur J Surg Oncol 1991; 17: 485-488.
63. Yamada K, Hayakawa T, Ushio Y, Arita N, Kato A, Mogami H. Regional blood flow and capillary permeability in the ethylnitrosourea-induced rat glioma. J Neurosurg 1981; 55: 922-928.
64. Mousseau M, Chauvin C, Nissou MF, et al. A study of the expression of four chemoresistance-related genes in human primary and metastatic brain tumours. Eur J Cancer 1993; 29A: 753-759.
65. Matsumoto T, Tani E, Kaba K, et al. Expression of P-glycoprotein in human glioma cell lines and surgical glioma specimens. J Neurosurg 1991; 72; 460-466.
66. Andrews DW, Das R, Kim S, et al. Technetium-MIBI as a glioma imaging agent for the assessment of multi-drug resistance. Neurosurgery 1997; 40: 1323-1332.